Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged rem...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/22/8553 |
id |
doaj-79bdcf7bb4ef4cef905b93e0bdfb613a |
---|---|
record_format |
Article |
spelling |
doaj-79bdcf7bb4ef4cef905b93e0bdfb613a2020-11-25T04:06:16ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-11-01218553855310.3390/ijms21228553Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell LymphomaLeonard Jeff Harris0Kruti Patel1Michael Martin2Oncology Division, Department of Medicine, University of Tennessee Health Sciences Center, Memphis, TN 38103, USAOncology Division, Department of Medicine, University of Tennessee Health Sciences Center, Memphis, TN 38103, USAWest Cancer Center & Research Institute, Memphis, TN 38103, USAThe most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy. Antibody-drug conjugates (ADC’s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide (LEN) in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed/refractory DLBCL.https://www.mdpi.com/1422-0067/21/22/8553Relapsed or Refractory Diffuse Large B Cell LymphomaDLBLCimmunotherapychemotherapy-free regimen |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Leonard Jeff Harris Kruti Patel Michael Martin |
spellingShingle |
Leonard Jeff Harris Kruti Patel Michael Martin Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma International Journal of Molecular Sciences Relapsed or Refractory Diffuse Large B Cell Lymphoma DLBLC immunotherapy chemotherapy-free regimen |
author_facet |
Leonard Jeff Harris Kruti Patel Michael Martin |
author_sort |
Leonard Jeff Harris |
title |
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
title_short |
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
title_full |
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
title_fullStr |
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
title_full_unstemmed |
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
title_sort |
novel therapies for relapsed or refractory diffuse large b-cell lymphoma |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2020-11-01 |
description |
The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy. Antibody-drug conjugates (ADC’s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide (LEN) in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed/refractory DLBCL. |
topic |
Relapsed or Refractory Diffuse Large B Cell Lymphoma DLBLC immunotherapy chemotherapy-free regimen |
url |
https://www.mdpi.com/1422-0067/21/22/8553 |
work_keys_str_mv |
AT leonardjeffharris noveltherapiesforrelapsedorrefractorydiffuselargebcelllymphoma AT krutipatel noveltherapiesforrelapsedorrefractorydiffuselargebcelllymphoma AT michaelmartin noveltherapiesforrelapsedorrefractorydiffuselargebcelllymphoma |
_version_ |
1724431681389068288 |